Been looking at some solid biotech investment opportunities for 2026 and honestly, there are a couple names that keep showing up on my radar.

First up is Regeneron. What caught my attention is how their core drugs are actually performing. Dupixent is printing money - global sales jumped 34% recently, and their eye disease treatment Eylea HD is even more impressive with 66% growth in the US market. They've also got momentum in cancer immunotherapy with Libtayo generating double-digit growth. The pipeline looks pretty loaded too with late-stage programs across hematology, immunology, and rare diseases.

The valuation is actually reasonable right now at 17x forward earnings. If you look back, this stock was trading at 25x+ not long ago, so there's definitely been a reset.

Then there's Vertex Pharmaceuticals. These guys basically own the cystic fibrosis space. Their CFTR modulators are treating about 90% of CF patients and they've got strong IP protection that should hold their position well into the next decade. But here's what's exciting - they're not just a one-trick pony anymore. They got approval for Casgevy, a gene-editing treatment for blood disorders, and Journavx for pain management. This diversification could be a major revenue driver.

Vertex is trading at 24x forward earnings, which feels fair given what they're building. Their CF drugs alone are generating billions, and the new approvals could really accelerate things.

For anyone thinking about biotech investment exposure right now, these two have proven track records with actual revenue, strong pipelines, and reasonable valuations. The combination of growth potential plus some stability from established products is pretty attractive for 2026. Worth digging deeper into both if you're looking to add some biotech to your portfolio.